Hormone Disorder Treatment

Pasireotide (MEQSEL) Tablet

$5,141.00

Efforts should be made to ensure equitable access to Pasireotide MEQSEL FCT 0.5/2MG Tablet for eligible patients, including exploring financial assistance programs and insurance coverage options to mitigate any financial barriers to treatment. Access to innovative medications is crucial to improve patient outcomes and quality of life.

Strength	Choose an option0.5mg2mg
	Clear

Quantity

Pasireotide (MEQSEL) Tablet quantity

Add to cart

Sku:

N/A

Tag:

Pasireotide MEQSEL

Description

Pasireotide MEQSEL FCT 0.5/2MG Tablet represents a significant advancement in the treatment of patients with Cushing’s disease or acromegaly, offering targeted therapy to mitigate the symptoms and underlying causes of these challenging endocrine disorders. This innovative medication contains pasireotide as its active ingredient, a somatostatin analog that binds to multiple somatostatin receptor subtypes, exerting potent inhibitory effects on hormone secretion.

Key Features:

• Somatostatin Receptor Analog: Pasireotide acts as a somatostatin receptor analog, binding to somatostatin receptors (SST1, SST2, SST3, and SST5) with high affinity. By binding to these receptors, pasireotide inhibits the secretion of adrenocorticotropic hormone (ACTH) in patients with Cushing’s disease and growth hormone (GH) in patients with acromegaly, effectively controlling hormone hypersecretion.
• Treatment of Cushing’s Disease and Acromegaly: Pasireotide MEQSEL FCT 0.5/2MG Tablet is indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative, as well as for the treatment of adult patients with acromegaly who have had an inadequate response to surgery or other medical therapies.
• Oral Administration: Pasireotide MEQSEL FCT 0.5/2MG Tablet is administered orally, typically twice daily with meals, to optimize absorption and minimize gastrointestinal side effects. The convenient dosing regimen enhances patient compliance and adherence to treatment.
• Efficacy: Clinical studies have demonstrated the efficacy of pasireotide in normalizing urinary free cortisol levels in patients with Cushing’s disease and normalizing insulin-like growth factor 1 (IGF-1) levels in patients with acromegaly. Pasireotide offers a valuable treatment option for patients who have not responded to conventional therapies or for whom surgical intervention is not feasible.
• Side Effects: Common side effects associated with pasireotide may include hyperglycemia, diarrhea, nausea, and abdominal pain. Patients should be closely monitored for adverse reactions, and dose adjustments may be necessary to manage side effects effectively.
• Patient Education: Patients prescribed Pasireotide MEQSEL FCT 0.5/2MG Tablet should receive comprehensive education regarding proper medication administration, potential side effects, and the importance of adherence to treatment. This empowers patients to actively participate in their healthcare management and optimize therapeutic outcomes.
• Consultation with Healthcare Provider: Treatment with Pasireotide MEQSEL FCT 0.5/2MG Tablet should be initiated and monitored by a qualified endocrinologist or healthcare provider experienced in the management of Cushing’s disease and acromegaly. Close monitoring and regular follow-up are essential to ensure optimal therapeutic response and patient safety.
• Access and Affordability: Efforts should be made to ensure equitable access to Pasireotide MEQSEL FCT 0.5/2MG Tablet for eligible patients, including exploring financial assistance programs and insurance coverage options to mitigate any financial barriers to treatment. Access to innovative medications is crucial to improve patient outcomes and quality of life.

Additional information